Economy/Home · Economy

Hengrui Pharma's HER2 ADC 'Ruikang Trastuzumab' Enters Priority Review in China for First-Line Breast Cancer Indication... Cumulative R&D of 2.361 Billion Yuan

China's Hengrui Pharmaceuticals has moved to expand the first-line breast cancer indication for its independently developed HER2-targeted antibody-drug conjugate (ADC), 'Ruikang trastuzumab (瑞康曲妥珠单抗).' With China's regulatory authorities accepting the marketing application and placing it in the prio

Wooil Shim
Staff Reporter
12 min read
Hengrui Pharma's HER2 ADC 'Ruikang Trastuzumab' Enters Priority Review in China for First-Line Breast Cancer Indication... Cumulative R&D of 2.361 Billion Yuan
CBC News

China's Hengrui Pharmaceuticals has moved to expand the first-line breast cancer indication for its independently developed HER2-targeted antibody-drug conjugate (ADC), 'Ruikang trastuzumab (瑞康曲妥珠单抗).' With China's regulatory authorities accepting the marketing application and placing it in the priority review process, attention is focused on the review outcome.

Marketing Application Accepted... Included in Priority Review

Jiangsu Hengrui Pharmaceuticals (恒瑞医药·600276.SH), a company listed on the Shanghai Stock Exchange, announced in a disclosure on the 29th that its subsidiary Suzhou Shengdiya Biopharmaceutical received a notice of acceptance for the marketing application of Ruikang trastuzumab for injection from China's National Medical Products Administration. The application targets first-line treatment of patients with locally advanced or metastatic HER2-positive breast cancer, and the drug is being developed for use in combination with pertuzumab or as monotherapy.

Hengrui explained that this application has been included in the priority review process of China's regulatory authorities. However, the application is currently at the acceptance stage, and final marketing approval for the new indication has not yet been confirmed.

HER2-Targeted ADC... Already Approved for Three Indications

Ruikang trastuzumab is a HER2-targeted ADC therapy independently developed by Hengrui. It works by binding to the HER2 protein on tumor cells, then being internalized into the cells and releasing its anticancer payload. According to the company, this process induces cell cycle arrest and apoptosis in tumor cells, and may also produce a 'bystander effect' affecting surrounding tumor cells.

The drug is currently approved in China for three indications: adult patients with unresectable locally advanced or metastatic non-small cell lung cancer harboring HER2-activating mutations who have received at least one prior systemic therapy; adult patients with locally advanced or metastatic HER2-positive breast cancer who have received HER2-targeted therapy at least once; and adult patients with HER2-positive colorectal cancer who have failed treatment with oxaliplatin, fluorouracil, and irinotecan. This application aims to expand the indication beyond previously treated patients into the first-line treatment setting for HER2-positive breast cancer.

Phase 3 Trial Shows Statistically Significant Improvement in Progression-Free Survival

The basis for the new indication application is a Phase 3 clinical trial (SHR-A1811-307) involving 75 research institutions across China. The trial enrolled HER2-positive breast cancer patients who had not received systemic anticancer therapy in the recurrent or metastatic setting. Researchers evaluated the efficacy and safety of Ruikang trastuzumab monotherapy or in combination with pertuzumab against the standard docetaxel, trastuzumab, and pertuzumab (THP) regimen, with progression-free survival (PFS) as the primary endpoint.

Hengrui stated that both monotherapy and the pertuzumab combination regimen statistically significantly extended progression-free survival compared with the control group, and confirmed a reduction in the risk of disease progression or death. However, the disclosure did not provide specific figures such as median PFS or hazard ratio (HR). The study was co-led by Professor Zhang Zefei of the Fifth Medical Center of the Chinese People's Liberation Army General Hospital and Professor Yin Yongmei of Jiangsu Province Hospital.

376,000 New Breast Cancer Cases Annually... Unmet Treatment Need Remains

Hengrui noted that demand for new therapies still exists in the treatment of HER2-positive breast cancer. Chinese cancer statistics cited by the company put new female breast cancer cases at 376,000 annually, with HER2-positive breast cancer accounting for approximately 15–20% of all breast cancers.

Expanding R&D Scope... Cumulative Investment of 2.361 Billion Yuan

The research and development scope of Ruikang trastuzumab is also expanding. Clinical studies are currently underway in non-small cell lung cancer and breast cancer, as well as gastric cancer, gastroesophageal junction adenocarcinoma, colorectal cancer, biliary tract cancer, ovarian cancer, and cervical cancer. The company said the drug has received a total of 11 innovative therapy designations from China's Center for Drug Evaluation (CDE).

The scale of R&D investment was also disclosed. According to Hengrui, cumulative R&D spending on Ruikang trastuzumab-related projects amounts to approximately 2.361 billion yuan, a figure that has not been externally audited. Citing EvaluatePharma statistics, the company said global sales of drugs in the same class reached approximately 8.157 billion USD in 2025. Products in the same class sold in China include Roche's trastuzumab emtansine and trastuzumab deruxtecan, jointly developed by AstraZeneca and Daiichi Sankyo.

Approval and Timing Undetermined... 'Uncertainties Exist at Each Stage'

Hengrui stated that uncertainties may arise at multiple stages, from drug development through clinical trials, approval, and commercialization. It added that it plans to disclose relevant information as R&D and review progress. With the inclusion in priority review, Chinese regulators will now review Ruikang trastuzumab for the first-line HER2-positive breast cancer indication, but final approval and its timing remain undetermined.

[The clinical trial results and R&D status are based on company disclosures and do not mean that final marketing approval for the new indication has been granted. The efficacy and safety of the drug should be judged based on the regulatory authorities' final review results. AI assistance was used in part.]

Wooil Shim
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.